Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis

被引:7
作者
Lee, Ji Yae [1 ]
Kim, Sue [2 ]
Lee, Yaeji [3 ]
Kwon, Yu-Jin [4 ]
Lee, Ji-Won [1 ,5 ]
机构
[1] Yonsei Univ, Severance Hosp, Coll Med, Dept Family Med, Seoul 03722, South Korea
[2] Yonsei Univ Hlth Syst, Severance Hosp, Int Hlth Care Ctr, Seoul 03722, South Korea
[3] Yonsei Univ, Dept Biostat & Comp, Seoul 03722, South Korea
[4] Yonsei Univ, Yongin Severance Hosp, Coll Med, Dept Family Med, Yongin 16995, South Korea
[5] Yonsei Univ, Severance Hosp, Dept Family Med, Coll Med,Inst Innovat Digital Healthcare, Yonsei Ro 50-1, Seoul 03722, South Korea
基金
新加坡国家研究基金会;
关键词
Mediterranean diet adherence; steatotic liver disease; metabolic dysfunction-associated steatotic liver disease; alcohol-related liver disease; CARDIOVASCULAR-DISEASE; HEPATIC STEATOSIS; GUIDELINE; BENEFITS; NOMENCLATURE; NUTRITION; HEALTH;
D O I
10.3390/nu16203551
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and Aims: Metabolic liver disease is associated with obesity, insulin resistance, cardiovascular disease, and metabolic disorders. A Mediterranean diet (MD), known for its anti-inflammatory and antioxidant properties, is effective in managing various chronic diseases, including liver diseases. This study aimed to explore the influence of adherence to the MD on the risk of chronic metabolic diseases, including steatotic liver disease (SLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-related liver diseases (ALDs). Methods: This retrospective cohort study analyzed 5395 individuals from a single center between 2020 and 2022, grouped by adherence to the MD using the Korean Mediterranean Diet Adherence Score (K-MEDAS). MASLD score, ALD, and cardiovascular risk factors were also assessed. Statistical analyses were performed using 1:1 exact matching and multiple regression to compare the less adherent (K-MEDAS 0-7) and highly adherent (K-MEDAS 8-13) groups. Results: Adjusting for confounding variables, high adherence to the MD was significantly associated with lower rates of SLD (odds ratio [OR] 0.818, 95% confidence interval [CI] 0.700-0.957, p = 0.012), MASLD (OR 0.839, 95% CI 0.714-0.986, p = 0.033), and ALD (OR 0.677, 95% CI 0.671-0.683, p < 0.001). Post-propensity score matching analysis revealed that the highly adherent group exhibited significantly lower triglyceride levels, triglyceride and glucose index, atherogenic Index of Plasma, and Framingham risk scores than the less adherent group. Conclusions: Good adherence to the MD considerably reduces the risk of SLD, MASLD, and ALD, underscoring its protective effects and potential to prevent metabolic liver diseases and their complications.
引用
收藏
页数:11
相关论文
共 50 条
[41]   Food insecurity is a risk factor for metabolic dysfunction-associated steatotic liver disease in Latinx children [J].
Maxwell, Sarah L. ;
Price, Jennifer C. ;
Perito, Emily R. ;
Rosenthal, Philip ;
Wojcicki, Janet M. .
PEDIATRIC OBESITY, 2024, 19 (06)
[42]   Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice? [J].
Gambardella, Maria Luisa ;
Abenavoli, Ludovico .
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (02)
[43]   Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer [J].
Moon, Sang Yi ;
Son, Minkook ;
Cho, Jung-Hwan ;
Kim, Hye In ;
Han, Ji Min ;
Bae, Ji Cheol ;
Suh, Sunghwan .
THYROID, 2025, 35 (01) :79-86
[44]   Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease [J].
Fu, Yu ;
Hua, Yuxin ;
Alam, Naqash ;
Liu, Enqi .
NUTRIENTS, 2024, 16 (18)
[45]   Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease [J].
El-Kassas, Mohamed ;
Awad, Abeer ;
Elbadry, Mohamed ;
Arab, Juan Pablo .
SEMINARS IN LIVER DISEASE, 2024, 44 (01) :54-68
[46]   Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction [J].
Zhou, Da ;
Fan, Jiangao .
CHINESE MEDICAL JOURNAL, 2024, 137 (22) :2687-2696
[47]   Active role of the immune system in metabolic dysfunction-associated steatotic liver disease [J].
Mori, Taizo ;
Yoshio, Sachiyo ;
Kakazu, Eiji ;
Kanto, Tatsuya .
GASTROENTEROLOGY REPORT, 2024, 12
[48]   Trends and Disparities in Cardiovascular Disease in US Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease [J].
Zhang, Yanbing ;
Zhang, Xinge ;
Huang, Chuiguo ;
Zhu, Lei .
BIOMEDICINES, 2025, 13 (04)
[49]   Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis [J].
Zhou, Like ;
Sun, Dongmei ;
Bai, Houqiao .
FRONTIERS IN NUTRITION, 2025, 12
[50]   Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)? [J].
Kasprzak-Drozd, Kamila ;
Nizinski, Przemyslaw ;
Kasprzak, Paulina ;
Kondracka, Adrianna ;
Oniszczuk, Tomasz ;
Rusinek, Agata ;
Oniszczuk, Anna .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)